Of these segments, anti-hypertensives and cholesterol-lowering drugs are emerging as the most promising therapy class owing to the development of drugs targeting proprotein
convertase subtilisin/kexin type 9 (PCSK9) and cholesteryl ester transfer protein (CETP).
Proteins that enter the secretory pathway are initially synthetized as biologically inactive precursors requiring proteolytic cleavage by highly specialized and evolutionarily conserved proprotein
Furin is a ubiquitous proprotein
convertase enriched in the trans-Golgi network and is well-conserved among mammals (20).
29 PCSK7 proprotein
convertase subtilisin/kexin type -0.
Combinatorial Environmental Stress and Subtilisin-like Proprotein
Persons with genetically lifelong low LDL-C levels--resulting from hypobetalipoproteinaemia or loss-of-function mutations in the proprotein
convertase subtilisin/kexin type 9 (PCSK9) gene--have a markedly reduced risk (80-90%) of developing CAD, despite a similar prevalence of other CVD risk factors.
Among the other 15 papers in these proceedings are discussions of extragastrointestinal functions and the transcriptional regulation of secretin and secretin receptors, PACAP as a master regulator of neuroendocrine stress circuits and the cellular stress response, the development of the zebrafish hypothalamus, the behavioral effect of neuropeptides related to feeding regulation in fish, and what lies ahead for the proprotein
Recently, a third gene, proprotein
convertase subtilisin/ kexin type 9 (PCSK9), causing autosomal dominant hypercholesterolemia Type 3 (OMIN 603776) has been described.
convertase promotes the degradation of the receptor responsible for eliminating LDL-cholesterol particles.
In the budding yeast Saccharomyces cerevisiae, Kex2p is a membrane-bound proprotein
processing protease (PPP) required for proper mating function.
The program, in collaboration with University of Texas (UT) Southwestern Medical Center at Dallas, is focused on evaluating new approaches for reducing LDL cholesterol levels using RNAi therapeutics directed to the disease target called proprotein
convertase subtilisn/kexin type 9, or PCSK9.
ALN-PCS is a systemically delivered RNAi therapeutic targeting the gene proprotein
convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol).